- Home >
- Clinicals Trials >
- ESTROTIMP
Retour à la liste des essais cliniques
ESTROTIMP
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP)
- Ouvert à Paris depuis le : 16/01/2023
- Ouvert à Saint-Cloud depuis le : 17/01/2023
- Public cible : Adult
- Phase : Phase IV
Description de l'essai
This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on the therapeutic management of patients with metastatic breast cancer (MBC).;Each patient will be screened to determine whether the patient meets all the inclusion criteria and none of the exclusion criteria.;After inclusion, a standardized pre ESTROTEP PET/CT questionnaire will be completed by the investigators to evaluate the initial management plan. Patient will perform the ESTROTEP PET/CT examination at visit 2. A standardized post ESTROTEP PET/CT questionnaire will then be completed by the investigators.;Patients will be followed for 12 months to evaluate their clinical status and standard of care investigations.
Url of the trialInvestigateur principal
